Id: | acc0350 |
Group: | 1sens |
Protein: | p27 |
Gene Symbol: | CDKN1B |
Protein Id: | P46527 |
Protein Name: | CDN1B_HUMAN |
PTM: | phosphorylation |
Site: | Thr187 |
Site Sequence: | SPNAGSVEQTPKKPGLRRRQT |
Disease Category: | Cancer |
Disease: | Hepatocellular Carcinoma |
Disease Subtype: | |
Disease Cellline: | HuH-7 |
Disease Info: | |
Drug: | MIF4GD OV |
Drug Info: | - |
Effect: | modulate |
Effect Info: | "In hepatocellular carcinoma (HCC) cells, MIF4GD binds to p27 and inhibits the phosphorylation of p27, thereby stabilizing p27. Overexpression of MIF4GD leads to an increase in p27 levels and a reduction in cell proliferation." |
Note: | Non-conventional drugs |
Score: | 3.0 |
Pubmed(PMID): | 24336329 |
Sentence Index: | 24336329_4 |
Sentence: | Interaction with MIF4GD led to the stabilization of p27 both in the nucleus and in the cytoplasm in hepatocellular carcinoma (HCC) cells as a result of suppressed phosphorylation of p27 by CDK2 at threonine187. |
Sequence & Structure:
MSNVRVSNGSPSLERMDARQAEHPKPSACRNLFGPVDHEELTRDLEKHCRDMEEASQRKWNFDFQNHKPLEGKYEWQEVEKGSLPEFYYRPPRPPKGACKVPAQESQDVSGSRPAAPLIGAPANSEDTHLVDPKTDPSDSQTGLAEQCAGIRKRPATDDSSTQNKRANRTEENVSDGSPNAGSVEQTPKKPGLRRRQT
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACCDKN1B-Thr187 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | |
HGSC | |
ccRCC | |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
T | 187 | P | Breast cancer/tumor/carcinoma | Phosphorylation | 23769441 |
T | 187 | U | Lymphoma | Phosphorylation | 22492278 |
T | 187 | U | B-cell lymphoma | Phosphorylation | 21338280 |
T | 187 | U | Hepatocellular carcinoma | Phosphorylation | 33574916 |
T | 187 | U | Prostate cancer/carcinoma/adenocarcinoma | Phosphorylation | 23707764 |
T | 187 | U | T-cell acute lymphoblastic leukemia | Phosphorylation | 34407842 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.